All In Biotech

Drug Trial Radar · NCT05661955

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

Phase 1b/2 Study Investigating the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of the Anti-OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Urothelial Carcinoma, Renal Cell Carcinoma, or Melanoma

Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

113

Actual

Start

Jan 9, 2023

Primary completion

May 27, 2025

Study completion Oct 2026

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Dec 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the overall response rate, evaluate the antitumor activity, and characterize the safety and tolerability of BGB-A445 alone or in combination with tislelizumab in participants With Advanced or Metastatic Urothelial Carcinoma (UC), Renal Cell Carcinoma (RCC), or Melanoma

Conditions

  • Urothelial Carcinoma
  • Renal Cell Carcinoma
  • Melanoma
  • Non-mucosal Melanoma

Interventions

  • BGB-A445Drug

    administered intravenously

  • TislelizumabDrug

    administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) as Assessed by the InvestigatorTime frame: Up to approximately 26 months

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • The Second Hospital and Clinical Medical School, Lanzhou University

    Lanzhou, Gansu, China

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Sun Yat Sen University Cancer Center

    Guangzhou, Guangdong, China

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Liaoning Cancer Hospital and Institute

    Shenyang, Liaoning, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • Jining No1 Peoples Hospital West Branch

    Jining, Shandong, China

  • Shanxi Provincial Cancer Hospital

    Taiyuan, Shanxi, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.